Title : Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen.

Pub. Date : 2022 May 6

PMID : 35526097

1 Functional Relationships(s)
Compound Name
Protein Name
1 Mechanistically, Bifonazole binds ACE2 around residue K353, which consequently prevents association with RBD, thereby impacting entry and replication of Spike-pseudotyped viruses as well as native SARS-CoV-2 and its variants of concern (VOC). Fluoroglycofen surface glycoprotein Severe acute respiratory syndrome coronavirus 2